Physician

David W Greenwald, MD

According to 2025 Medicare claims, David Greenwald, MD (NPI: 1558380295) practices medical oncology in the Scranton--Wilkes-Barre, PA market, with the plurality of this provider's patient population coming from Luzerne, PA. This provider's primary affiliated billing organization is MEDICAL ONCOLOGY ASSOCIATES OF WYOMING VALLEY, PC (NPI: 1134120199; TIN: 232170323) and primary practice location at 18704-5535.

Greenwald's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,188 traditional Medicare patients, billed 489,342 HCPCS/CPT codes, and received $5,517,371 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,906 prescription claims across 322 beneficiaries totaling $7,085,057 in drug costs, led by Ibrance (Palbociclib). DME data shows 231 claims. Open Payments data shows 35 records totaling $595. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $3,511,896 to $5,517,371. Similarly, Part D prescription costs have risen steadily, from $3,001,804 to $7,085,057. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,482	307,565	$3,511,896
2016	1,319	331,957	$3,714,946
2017	1,279	345,653	$3,968,276
2018	1,311	383,140	$4,310,286
2019	1,249	322,297	$4,642,486
2020	1,209	383,414	$6,310,914
2021	1,234	382,281	$6,167,195
2022	1,196	363,368	$5,030,305
2023	1,199	442,814	$5,043,969
2024	1,188	489,342	$5,517,371

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	308	1,912	$3,001,804
2016	297	1,968	$3,967,636
2017	344	2,311	$4,495,738
2018	342	2,207	$4,783,994
2019	360	2,315	$5,386,798
2020	347	2,348	$6,803,008
2021	343	2,088	$6,153,795
2022	332	1,975	$5,995,385
2023	311	1,751	$5,842,684
2024	322	1,906	$7,085,057

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	112	257	$100,959
2016	68	228	$42,687
2017	89	213	$42,150
2018	17	109	$9,794
2019	71	138	$14,575
2020	43	101	$6,677
2021	39	106	$5,312
2022	50	125	$8,601
2023	49	173	$26,879
2024	76	231	$13,942

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	585	1,727	$95
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	429	575	$67
80053	Blood test, comprehensive group of blood chemicals	848	2,522	$10
36415	Insertion of needle into vein for collection of blood sample	760	1,698	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	1,068	3,688	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	111	3,108	$1,754,828
Imbruvica	Ibrutinib	45	1,260	$724,131
Lenvima	Lenvatinib Mesylate	18	540	$632,316
Revlimid	Lenalidomide	26	728	$545,378
Abiraterone Acetate	Abiraterone Acetate	130	3,900	$384,196

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8030	Breast prosthesis, silicone or equal, without integral adhesive	N	14	15	$6,844
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	22	31	$2,541
J8521	Capecitabine, oral, 500 mg	N	19	68	$2,287
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	21	83	$1,487
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	21	$620

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	35	$595	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for David W. Greenwald, MD?

Tedicare shows public-source Medicare data for David W. Greenwald, MD (NPI 1558380295), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does David W. Greenwald, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to David W. Greenwald, MD?

David W. Greenwald, MD is linked to MEDICAL ONCOLOGY ASSOCIATES OF WYOMING VALLEY, PC (billing NPI 1134120199) in the available physician profile data.

Does David W. Greenwald, MD have Open Payments data?

David W. Greenwald, MD has 35 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.